The FDA's July 2026 Peptide Review: What It Means for BPC-157, TB-500, Semax, and the Research Community

The FDA's Pharmacy Compounding Advisory Committee convened July 2324, 2026 to decide whether seven peptides — including BPC157, TB500, and Semax — should be eligible for legal compounding. Here's what happened, what it means, and why it matters.

For research use only. Not for human consumption.